Abstract
Although seaweeds have been used for decades as food, medicinal plants, and nutritional supplements, their use as a vaccine production and delivery platform has been barely explored, despite the availability of several genetic tools for seaweed transformation. The present review introduces seaweeds and their valuable immunomodulatory compounds in perspective as vaccine production and mucosal delivery platform. Genetic engineering tools are reviewed for macroalgal transformation, and the recombinant proteins produced in this platform are summarized. Finally, the hurdles and opportunities on seaweed potential as a vaccine production platform and delivery vehicle are proposed. As expected, seaweeds can soon be exploited to produce vaccine candidates due to their biological characteristics, including accelerated growth, photosynthetic capacity, and bioactive compound production, as well as the genetic engineering tools available. With all these properties -plus the commercial seaweed industry- this new envisioned technology can be adopted to improve human and animal health.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.